

## The Right Door for Hope, Recovery and Wellness

Chapter Title <b>Recipient Rights</b>	Chapter # <b>RR</b>		Subject # <b>137</b>
Subject Title <b>Clozaril (clozapine)</b>	Adopted  2/26/96	Last Revised  5/24/21	Last Reviewed 12/27/04; 12/27/06; 3/27/08; 7/12/10; 6/27/11; 5/29/12; 9/23/13; 12/10/14; 9/23/15; 12/14/16; 12/20/17; 12/19/18; 12/18/19; 4/26/21; 5/24/21

### **POLICY**

#### **Application**

This policy shall apply to The Right Door for Hope, Recovery and Wellness and all services operated by or under contract with it.

#### **1.0 Clozaril (clozapine)**

It is the policy of The Right Door for Hope, Recovery and Wellness Authority that Clozaril will be prescribed and monitored in strict compliance with the Risk Evaluation and Mitigation Strategy (REMS) and Food and Drug Administration (FDA) standards. Medication will not be dispensed without a favorable report of the blood analysis. Blood will be drawn for white blood cell (WBC) laboratory analysis and reporting as follows:

- 1.1 weekly: for the first six months;
- 1.2 bi-weekly: for the period of six months to one year;
- 1.3 monthly: after one year.

If a person served misses more than two days of their medication, they must start all over with weekly blood draws for six months etc. and this schedule is for those whose labs are normal and have been normal.

#### **References**

Food and Drug Administration (FDA) Standards  
CARF Standards, Section "Pharmacotherapy"

The Right Door for Hope, Recovery and Wellness

Chapter Title <b>Recipient Rights</b>	Chapter # <b>RR</b>		Subject # <b>137</b>
Subject Title <b>Clozaril (clozapine)</b>	Adopted  2/26/96	Last Revised  5/24/21	Last Reviewed 12/27/04; 12/27/06; 3/27/08; 7/12/10; 6/27/11; 5/29/12; 9/23/13; 12/10/14; 9/23/15; 12/14/16; 12/20/17; 12/19/18; 12/18/19; 4/26/21; 5/24/21

Melissa McKinstry, Board Chairperson	Date		